Cargando…

Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials

OBJECTIVES: The objective of this meta-analysis of randomised controlled trials (RCTs) is to evaluate the role of primary prevention implantable cardioverter defibrillator (ICD) in patients with non-ischaemic cardiomyopathy (NICM). SETTING: A meta-analysis of RCTs performed according to the Preferre...

Descripción completa

Detalles Bibliográficos
Autores principales: Barakat, Amr F, Saad, Marwan, Elgendy, Akram Y, Mentias, Amgad, Abuzaid, Ahmed, Mahmoud, Ahmed N, Elgendy, Islam Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726098/
https://www.ncbi.nlm.nih.gov/pubmed/28637742
http://dx.doi.org/10.1136/bmjopen-2017-016352
_version_ 1783285671508574208
author Barakat, Amr F
Saad, Marwan
Elgendy, Akram Y
Mentias, Amgad
Abuzaid, Ahmed
Mahmoud, Ahmed N
Elgendy, Islam Y
author_facet Barakat, Amr F
Saad, Marwan
Elgendy, Akram Y
Mentias, Amgad
Abuzaid, Ahmed
Mahmoud, Ahmed N
Elgendy, Islam Y
author_sort Barakat, Amr F
collection PubMed
description OBJECTIVES: The objective of this meta-analysis of randomised controlled trials (RCTs) is to evaluate the role of primary prevention implantable cardioverter defibrillator (ICD) in patients with non-ischaemic cardiomyopathy (NICM). SETTING: A meta-analysis of RCTs performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. DATA SOURCES: The PubMed, MEDLINE, Embase and Cochrane Central Register of Controlled Trials databases were searched for relevant articles. PARTICIPANTS: A total of 5 RCTs with 2573 patients with NICM were included. INTERVENTION: Primary prevention ICD, compared with medical therapy alone. PRIMARY AND SECONDARY OUTCOME MEASURES: All-cause mortality (primary outcome) and sudden cardiac death (SCD, secondary outcome). DATA ANALYSIS: Summary estimate HR were constructed using the random-effect DerSimonian and Laird’s model. Multiple study-level subgroup analyses were performed, and interaction was tested using random-effect analysis. RESULTS: Compared with medical therapy alone, ICD placement was associated with lower risk of all-cause mortality (HR 0.79; 95% CI 0.64 to 0.93; p<0.001; I(2)=0%) at a mean follow-up of 4.2 years. The risk of SCD was also lower with ICD placement (RR 0.47; 95% CI 0.30 to 0.73; p=0.001; I(2)=0%) compared with control. On subgroup analyses, there was a suggestion of possible effect modification by age, in which benefit was observed in age group <60 years (HR 0.64; 95% CI 0.47 to 0.89), but not with age ≥60 years (HR 0.82; 95% CI 0.65 to 1.03) (P(interaction)=0.058), but not with other study-level variables. CONCLUSIONS: Compared with medical therapy alone, primary prevention ICD therapy in patients with NICM is associated with a significant reduction in all-cause mortality, especially in younger patients. Future dedicated studies are needed to investigate the role of primary prevention ICD in the elderly population. PROSPEROREGISTRATIONNUMBER: PROSPERO CRD42016052010.
format Online
Article
Text
id pubmed-5726098
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-57260982017-12-20 Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials Barakat, Amr F Saad, Marwan Elgendy, Akram Y Mentias, Amgad Abuzaid, Ahmed Mahmoud, Ahmed N Elgendy, Islam Y BMJ Open Cardiovascular Medicine OBJECTIVES: The objective of this meta-analysis of randomised controlled trials (RCTs) is to evaluate the role of primary prevention implantable cardioverter defibrillator (ICD) in patients with non-ischaemic cardiomyopathy (NICM). SETTING: A meta-analysis of RCTs performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. DATA SOURCES: The PubMed, MEDLINE, Embase and Cochrane Central Register of Controlled Trials databases were searched for relevant articles. PARTICIPANTS: A total of 5 RCTs with 2573 patients with NICM were included. INTERVENTION: Primary prevention ICD, compared with medical therapy alone. PRIMARY AND SECONDARY OUTCOME MEASURES: All-cause mortality (primary outcome) and sudden cardiac death (SCD, secondary outcome). DATA ANALYSIS: Summary estimate HR were constructed using the random-effect DerSimonian and Laird’s model. Multiple study-level subgroup analyses were performed, and interaction was tested using random-effect analysis. RESULTS: Compared with medical therapy alone, ICD placement was associated with lower risk of all-cause mortality (HR 0.79; 95% CI 0.64 to 0.93; p<0.001; I(2)=0%) at a mean follow-up of 4.2 years. The risk of SCD was also lower with ICD placement (RR 0.47; 95% CI 0.30 to 0.73; p=0.001; I(2)=0%) compared with control. On subgroup analyses, there was a suggestion of possible effect modification by age, in which benefit was observed in age group <60 years (HR 0.64; 95% CI 0.47 to 0.89), but not with age ≥60 years (HR 0.82; 95% CI 0.65 to 1.03) (P(interaction)=0.058), but not with other study-level variables. CONCLUSIONS: Compared with medical therapy alone, primary prevention ICD therapy in patients with NICM is associated with a significant reduction in all-cause mortality, especially in younger patients. Future dedicated studies are needed to investigate the role of primary prevention ICD in the elderly population. PROSPEROREGISTRATIONNUMBER: PROSPERO CRD42016052010. BMJ Publishing Group 2017-06-21 /pmc/articles/PMC5726098/ /pubmed/28637742 http://dx.doi.org/10.1136/bmjopen-2017-016352 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Cardiovascular Medicine
Barakat, Amr F
Saad, Marwan
Elgendy, Akram Y
Mentias, Amgad
Abuzaid, Ahmed
Mahmoud, Ahmed N
Elgendy, Islam Y
Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials
title Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials
title_full Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials
title_fullStr Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials
title_full_unstemmed Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials
title_short Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials
title_sort primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726098/
https://www.ncbi.nlm.nih.gov/pubmed/28637742
http://dx.doi.org/10.1136/bmjopen-2017-016352
work_keys_str_mv AT barakatamrf primarypreventionimplantablecardioverterdefibrillatorinpatientswithnonischaemiccardiomyopathyametaanalysisofrandomisedcontrolledtrials
AT saadmarwan primarypreventionimplantablecardioverterdefibrillatorinpatientswithnonischaemiccardiomyopathyametaanalysisofrandomisedcontrolledtrials
AT elgendyakramy primarypreventionimplantablecardioverterdefibrillatorinpatientswithnonischaemiccardiomyopathyametaanalysisofrandomisedcontrolledtrials
AT mentiasamgad primarypreventionimplantablecardioverterdefibrillatorinpatientswithnonischaemiccardiomyopathyametaanalysisofrandomisedcontrolledtrials
AT abuzaidahmed primarypreventionimplantablecardioverterdefibrillatorinpatientswithnonischaemiccardiomyopathyametaanalysisofrandomisedcontrolledtrials
AT mahmoudahmedn primarypreventionimplantablecardioverterdefibrillatorinpatientswithnonischaemiccardiomyopathyametaanalysisofrandomisedcontrolledtrials
AT elgendyislamy primarypreventionimplantablecardioverterdefibrillatorinpatientswithnonischaemiccardiomyopathyametaanalysisofrandomisedcontrolledtrials